Filing Flows › Pacific Biosciences of California (PACB) › Guidance history
Pacific Biosciences of California (PACB) guidance history: what it guided and what it reported
Pacific Biosciences of California gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance 0 times and lowered it once.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $165M–$175M (May 7, 2026) → lowered $155M–$165M (Aug 5, 2026) → lowered $155M–$160M (Nov 4, 2026) | — | to be reported | — |
The latest quarter
Pacific Biosciences of California, Q3 2026: revenue $40.6M (+6% year over year), operating margin -91.2%, net loss $37.8M, operating cash flow −$37.6M. The chart follows the revenue to costs, profit and cash.
Questions
Does Pacific Biosciences of California beat its guidance?
Pacific Biosciences of California gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance 0 times and lowered it once.
How often does Pacific Biosciences of California raise guidance?
Its earnings releases raised guidance 0 times and lowered it once since May 7, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.